+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes



A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes



European Journal of Surgical Oncology 39(6): 554-558



Intraductal papillary mucinous neoplasm of the biliary tract (BT-IPMN) has been increasingly recognized as a biliary counterpart of intraductal papillary mucinous neoplasm of the pancreas (P-IPMN). However, there is limited information regarding whether BT-IPMNs and P-IPMNs behave in a similar fashion. We retrospectively compared clinicopathological variables between 9 patients with BT-IPMN and 44 patients with P-IPMN. There was no significant difference in age between patients with BT-IPMN and those with P-IPMN. The male/female ratio was significantly higher in patients with P-IPMN than in those with BT-IPMN (P = 0.012). Clinical presentation with jaundice was more common in patients with BT-IPMN (67%) than in those with P-IPMN (4.5%, P = 0.002). In addition, serum levels of CEA and CA19-9 were higher in patients with BT-IPMN than in those with P-IPMN (P = 0.019 and P = 0.002, respectively). The pathological diagnosis of malignancy was significantly more common in patients with BT-IPMN (89%) than in those with P-IPMN (23%, P = 0.002). The association with invasive carcinoma was significantly more frequent in patients with BT-IPMN (44.4%) than in those with P-IPMN (6.8%, P = 0.008). Furthermore, survival time after surgical resection was significantly shorter in patients with BT-IPMN than in those with P-IPMN (P = 0.002). These findings reveal differences in clinicopathological features and prognosis between BT-IPMN and P-IPMN, thereby suggesting distinct biological pathways underlying the pathogenesis of these neoplasms.

(PDF emailed within 0-6 h: $19.90)

Accession: 036809969

Download citation: RISBibTeXText

PMID: 23506840

DOI: 10.1016/j.ejso.2013.02.016


Related references

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): new insights on clinical outcomes and malignant progression. Jop 15(4): 310-312, 2015

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. Jop 14(2): 141-144, 2013

Su1476 Plectin-1 As a Biomarker for Malignant Progression in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. Gastroenterology 148(4): S-523-S-524, 2015

CEACAM1 expression in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: A factor of prognostic significance in invasive IPM-carcinomas. Journal of Gastrointestinal Surgery 9(4): 521-522, 2005

MRI findings of intraductal papillary mucinous neoplasms (IPMNs). Acta Bio-Medica 87 Suppl 3: 28-33, 2018

Multifocal branch-duct intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: magnetic resonance (MR) imaging pattern and evolution over time. La Radiologia Medica 118(6): 917-929, 2013

Epithelial cell adhesion molecule (EpCAM) overexpression is correlated with malignant potentials of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Biomedical Research 34(2): 87-95, 2013

Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife?. Gut 57(3): 287-289, 2008

Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Archiv 469(5): 523-532, 2016

Immunophenotypic features of intraductal papillary mucinous neoplasms of the pancreas Comparative immuno-histo-chemical analysis of oncoprotein expression in various components of IPMNs. Pancreas 21(4): 430, 2000

Tu1216 Epithelial Cell Adhesion Molecule (EpCam) Overexpression Is Correlated With Malignant Potentials of Intraductal Papillary Mucinous Neoplasms (Ipmns) of the Pancreas. Gastroenterology 144(5): S-794, 2013

Clinicopathologic features of re-resected cases of intraductal papillary mucinous neoplasms (IPMNs). Surgery 142(2): 136-142, 2007

Mo1510 Usefulness of Contrast-Enhanced Harmonic Endoscopic Ultrasonography (Ch-EUS) for Depiction of Papillary Growth Extension From Branches to the Main Duct in IPMNs (Intraductal Papillary Mucinous Neoplasms). Gastrointestinal Endoscopy 77(5): Ab408-Ab409, 2013

Mo1195 miRNA Can Identify Intraductal Papillary Mucinous Neoplasms (IPMNs) With Advanced Dysplasia. Gastroenterology 142(5): S-618-S-619, 2012

S1305 Does Fluid Cea Level Predict Malignancy in Intraductal Papillary Mucinous Neoplasms (Ipmns)?. Gastroenterology 136(5): A-233, 2009